+44-330-822-4832
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Research Article
Practical Application of a Comprehensive Weight Management Program in Patients with and without Metabolic Syndrome
| Jamy D Ard1*, Maria C Schroeder2, Kaisa Kivilaid3, Nicole M Soliday3, Julie A Swanson4, Ellyce A Hayes4, and Maryam N Kadjar Olesen5 | |
| 1Wake Forest University Baptist Medical Center, Medical Center Boulevard, USA | |
| 2Insight Advisor Group, USA | |
| 3Regulatory and Clinical Research Institute, Inc, USA | |
| 4Nestlé Health Science, Nutrition R and D Center Minneapolis, USA | |
| 5Nestlé Health Science, Switzerland | |
| Corresponding Author : | Jamy D Ard Wake Forest University Baptist Medical Center Medical Center Boulevard, Winston-Salem, NC 27157, USA Tel: 336-716-9837 Fax: 336-713-4300 E-mail: jard@wakehealth.edu |
| Received March 03, 2014; Accepted March 20, 2014; Published March 24, 2014 | |
| Citation: Ard JD, Schroeder MC, Kivilaid K, Soliday NM, Swanson JA, et al. (2014) Practical Application of a Comprehensive Weight Management Program in Patients with and without Metabolic Syndrome. J Obes Wt Loss Ther S4:007. doi:10.4172/2165-7904.S4-007 | |
| Copyright: © 2014 Ard JD, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | |
Abstract
This paper examines weight loss outcomes and their impact on risk factors associated with metabolic syndrome following participation in OPTIFAST®, a comprehensive weight-management program. A multicenter, retrospective chart review of 153 patients enrolled in the OPTIFAST program was conducted. Change in weight, body mass index, percent weight loss and cardiometabolic risk factors were compared between patients with and without metabolic syndrome. Patients with metabolic syndrome at baseline lost 21.6 ± 10.0 kg compared to 20.4 ± 9.2 kg for patients without metabolic syndrome (p > 0.05). Mean reduction in body mass index was 7.3 ± 3.1 kg/m2 and 7.1 ± 3.0 kg/ m2, and mean percent weight loss was 16.7 ± 6.9% and 17.6 ± 6.9%, respectively (p > 0.05). Metabolic syndrome patients had significantly greater reductions in triglycerides (p < 0.0001) and diastolic blood pressure (p < 0.01). The proportion of metabolic syndrome patients at program completion (41/87 (47%)) was significantly less than the proportion of metabolic syndrome patients at baseline (51/87 (59%); p < 0.0001). Patients with and without metabolic syndrome achieved significant weight loss and similar declines in body weight, body mass index and percent weight change. Significant improvements in cardiometabolic risk factors, including meaningful reductions in the prevalence of metabolic syndrome within the study population were observed.
